Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111M
-
Number of holders
-
250
-
Total 13F shares, excl. options
-
89.2M
-
Shares change
-
+215K
-
Total reported value, excl. options
-
$3.7B
-
Value change
-
-$22.4M
-
Put/Call ratio
-
0.34
-
Number of buys
-
100
-
Number of sells
-
-148
-
Price
-
$41.50
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q2 2023
345 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q2 2023.
NovoCure Ltd - Common Stock (NVCR) has 250 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.2M shares
of 111M outstanding shares and own 80.27% of the company stock.
Largest 10 shareholders include FMR LLC (15.9M shares), Capital World Investors (11.4M shares), VANGUARD GROUP INC (9.66M shares), Capital International Investors (8.81M shares), BAILLIE GIFFORD & CO (8.69M shares), BlackRock Inc. (8.12M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.55M shares), STATE STREET CORP (2.47M shares), T. Rowe Price Investment Management, Inc. (1.89M shares), and Nordwand Advisors, LLC (1.52M shares).
This table shows the top 250 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.